Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Amantadin resistant variants of influenza A virus from Flu-like infected suspects in a Children Infectious Research Center in Tehran, Iran

The matrix protein 2 (M2) blocker, Amantadin, is approved by FDA to treat and control of influenza A virus infections in children and adults. Recently, some substitutions at amino acid positions are causing the emergence of anti viral drug-resistant strains of influenza virus.

To investigate the frequency of Amantadin resistance among influenza A viruses isolated in children (up to 10 years old) referring to Children Infectious Research Center in Tehran – Iran during the 2008 – 2009 Flu season, 124 samples were collected. Forty cases from them were detected as influenza A virus by Reverse transcriptase polymerase chain reaction (RT-PCR). The Large subunit of hemagglutinin (HA1) and M2 genes were amplified by RT-PCR followed by sequencing.

62.5% of positive cases were 0-3 years, 10% of them were 4-6 years, and 27.5% were 7- 10 years. The result shows 70% were male. 50% of positive cases affected sporadic. Clinical symptoms in these positive cases were as follows: Sudden onset 51%, fever 69.4%, headache 21.8%, coryza 82.5%, weakness 54.8%, pharingitis 41.1%, bronchodyspenia 4%, cough 11.3%, agitation 58%, sputum 59.7%, and muscle pain 8%, gastrointestinal problem, 23.4%, otitis 13%. 97.5% of these forty cases did not received influenza vaccine and 40% received antibiotic.

Our data show that Amantadin resistant A/H3 N2 is caused by a single amino acid mutation that makes a Ser 31 Asp substitution in M2 protein. Since these children might not used Amantadin, the drug resistance determined in this project is not related to direct usage of Amantadin by the patient. Continued surveillance is required to elucidate full Amantadin-resistant pattern of influenza virus in Iranian children, especially in the recent pandemics.

Author information

Correspondence to Zahra Shokati Eshkiki.

Rights and permissions

This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Reprints and Permissions

About this article

Cite this article

Eshkiki, Z.S., Fotouhi, F., Mazaheri, V. et al. Amantadin resistant variants of influenza A virus from Flu-like infected suspects in a Children Infectious Research Center in Tehran, Iran. BMC Proc 5, P63 (2011). https://doi.org/10.1186/1753-6561-5-S1-P63

Download citation

Keywords

  • Influenza
  • Influenza Virus
  • Reverse Transcriptase Polymerase Chain Reaction
  • Positive Case
  • Influenza Vaccine